SVN-015 Advances into Further NIDA-Funded Studies

AI SummaryClose X

Solvonis Therapeutics plc announced that its stimulant-use-disorder candidate, SVN-015, has demonstrated encouraging initial in vitro cardiac ion-channel and broader off-target screening results under the U.S. National Institute on Drug Abuse's Addiction Treatment Discovery Program. Following these positive findings, NIDA will advance SVN-015 into further preclinical evaluation, including confirmatory transporter and in vivo studies, which will be funded by NIDA. The company highlighted that SVN-015 showed a more favourable cardiac ion-channel profile compared to GBR-12909, a known dopamine transporter inhibitor. This progression is a significant milestone, providing external validation and access to specialist research capabilities without diluting equity.

Disclaimer*

UK 100

Latest directors dealings